E. Lévy
Albert Einstein College of Medicine(US)
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Immunotherapy and Immune Responses, Nail Diseases and Treatments, Chemotherapy-related skin toxicity, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial(2019)126 cited
- Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients.(2001)
- → Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients(2010)38 cited
- → A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC)(2006)34 cited
- → Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group(2009)24 cited
- → Radiation-induced bone sarcoma following total body irradiation: role of additional radiation on localized areas(2000)15 cited
- → Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines(2011)14 cited
- → Cancers anaplasiques de la thyroïde. La guérison est-elle possible ?(1999)14 cited
- → Vitiligo post-greffe thymique chez un enfant porteur d’un déficit en Foxn1(2012)10 cited
- → Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer (HRPC) patients. A meta-analysis of 3-year overall survival results(2005)9 cited